Objective:

To outline the changes in cancer reporting protocols for head and neck cancers by the College of American Pathologists (CAP).

Key Findings:

• Introduction of specific protocols for HPV-associated oropharyngeal cancer, nasopharyngeal tumors, and others.
• New section on tumor bed margin status and expanded lymph node reporting.
• Mandatory reporting of previously optional data points for clinical decision-making.
• Revised biomarker reporting criteria, including HER2 scoring and new antibodies.
• Refinements in terminology and tumor descriptions to enhance clarity and consistency.

Interpretation:

The updates reflect a deeper understanding of head and neck cancers, particularly regarding HPV-related tumors, and aim to improve diagnostic accuracy and treatment planning.

Limitations:

• The article does not provide specific examples of how the changes will be implemented in practice.
• Potential challenges in training pathologists on the new protocols are not addressed.

Conclusion:

The updated CAP protocols signify a commitment to precise and clinically actionable reporting in head and neck cancer pathology, enhancing the integration of molecular and biomarker information.